Brief: Fresenius Says Fresenius Kabi Enters Partnership With U.S. Phlow To Establish Supply Chain For Epinephrine
Feb 9 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE: FRESENIUS KABI ENTERS PARTNERSHIP WITH U.S. MANUFACTURER PHLOW CORP. TO ESTABLISH A DOMESTIC, END TO END SUPPLY CHAIN FOR EPINEPHRINE INJECTION, USP EPINEPHRINE PRODUCED THROUGH THIS COLLABORATION COULD BE AVAILABLE TO U.S. HOSPITALS IN 2027 Further company coverage: FREG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)